Abstract
It has been postulated that favouring the absorption of interleukin-2 via lymphatics rather than venous capillaries after subcutaneous administration may improve its therapeutic index. We have now evaluated in 12 cancer patients the plasma pharmacokinetic of interleukin-2 either dissolved in water or in 20% albumin solution with an internal cross-over after at least three days. Our data show that when albumin is present, the plasma concentrations of interleukin-2 versus time is increased and swelling at the injection sites is reduced. It remains to be seen whether efficacy improves during a prolonged treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use
-
Female
-
Humans
-
Injections, Subcutaneous
-
Interleukin-2 / adverse effects
-
Interleukin-2 / pharmacokinetics*
-
Interleukin-2 / therapeutic use
-
Lymphatic System / metabolism*
-
Male
-
Middle Aged
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / pharmacokinetics
-
Recombinant Proteins / therapeutic use
-
Serum Albumin / pharmacokinetics
Substances
-
Antineoplastic Agents
-
Interleukin-2
-
Recombinant Proteins
-
Serum Albumin